You do know how early VAXINIA and OASIS clinical trials are don't you???? Sure, Azer-Cel is more advance given Precision already conducted Ph1 clinical trial before IMU acquired the IP but there was question around toxicity which IMU still encountered with Cohort A.
Like I've told you countless time, BP don't act this early on anything, they will show interest end of Ph1 clinical trial because of the efficacy already shown otherwise they usually act after the completion of Ph2 clinical trial.
If you are questioning the quality of shareholder represented then look at yourself, you contribute nothing beside whingeing about LC. If you can't see what she has achieved in the last 14 months is very important in the lead up to the next 3-6 months and then start of Ph2 clinical trial end of this year then you are as clueless as @mrdingo and need to sell.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)